Press Release

Humanized Mice Model Market to Grow with a CAGR of 9.80% through 2029

Rising demand for personalized medicine and growing pipeline of pharmaceutical and biopharmaceutical companies is to drive the Global Humanized Mice Model Market growth in the forecast period, 2025-2029.

 

According to TechSci Research report, “Humanized Mice Model Market – Global Industry Size, Share, Trends, Competition, Forecast & Opportunities, 2029”, the Global Humanized Mice Model Market stood at USD 1.15 billion in 2023 and is anticipated to grow with a CAGR of 9.80% in the forecast period, 2025-2029. Factors such as the continuous advancements in mice models, the escalating demand for personalized medicine, and the expanding pipeline of pharmaceutical and biopharmaceutical companies are fueling the growth of the mice model market.

The utilization of mice models for the identification of immunodeficiency disorders, cancers, and other rare diseases, coupled with the increase in research and development activities conducted by pharmaceutical and biotechnology companies, has contributed to the growing demand for personalized mice models. The continuous support and initiatives from governments and private sectors for research on mice models, along with the adoption of modified medicines, have further fueled this demand. Technological advancements, the rising prevalence of cancer, ongoing research and development activities, and the increasing adoption of personalized medicines are key factors projected to drive the Global Humanized Mice and Rat Model Market. Notably, government investments play a crucial role in stimulating this market.

Mice models are considered to be among the most effective small animal models for studying various infectious diseases, including hepatitis B virus (HBV), hepatitis C virus (HCV), Zika virus, and cytomegalovirus (CMV), among others. Their use in pre-clinical research has significantly contributed to our understanding of viral infections and the development of potential treatments. In a recent article titled "Novel App knock-in mice model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia," published in June 2022, it was highlighted that the genetic engineering of novel mice models using knock-in approaches has helped overcome some of the limitations associated with genetic mutations. This approach opens up new possibilities for studying disease mechanisms and developing targeted therapies. The article also emphasized the importance of open-access mice models as valuable resources for studying disease-relevant biology.

Mice possess several advantages over other model organisms. Their genome is remarkably similar to the human genome, sharing about 99% of its genetic sequence. This genetic similarity enables researchers to translate findings from mice studies to human diseases more effectively. Mice offer a robust genetic and molecular toolkit, allowing for sophisticated manipulation and analysis of genes and proteins. Their small size makes them a cost-effective model for large-scale, high-throughput research. In an article titled "How Necessary are Animal Models for Modern Drug Discovery?" published in September 2021, it was noted that advancements in human tissue engraftment techniques and the development of humanized mice models have significantly contributed to our understanding of human diseases. These humanized mice models, with transplanted tissues that can perform close to normal organ and tissue functions, offer a valuable platform for studying disease mechanisms and evaluating potential therapeutic interventions. Considering the numerous advantages and applications of mice models, their demand is expected to continue growing, thereby driving the overall market growth in the foreseeable future.

Humanized mice models have been developed to overcome limitations of traditional mice models, such as differences in immune systems. These models are crucial in preclinical research, as they can replicate human pathological conditions and evaluate the effectiveness of immunotherapy approaches. They are used in studies of infectious diseases, transplantation, regenerative medicine, and cancer biology. Humanized mice models have also played a significant role in the development of vaccines and antibody-based therapies for COVID-19. Scientists have created a triple immunodeficient humanized mice model that engrafts CD34+ cord blood and supports the production of human immune cells expressing ACE2, the receptor used by the coronavirus to enter human cells. These models, along with others developed since the COVID-19 outbreak, are expected to enhance our understanding of SARS-CoV-2 infection, the efficacy of antiviral therapies, and aid in the development of effective drugs for treatment and prevention of this disease.

Rapid technological advancements and genetic engineering of the mice genome have contributed to significant revenue growth in this market. This trend is expected to continue in the future.

                                                                                             

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Humanized Mice Model Market 

The Global Humanized Mice Model Market is segmented into type, application, end user, regional distribution, and company.

Based on its application, the market is segmented into oncology, immunology & infectious diseases, toxicology, and others. The Oncology segment is projected to hold a significant market share throughout the forecast period. The application of mice models in oncology is anticipated to experience substantial growth, driven by the increasing burden of cancer and the adoption of mice models in drug and vaccine development research. The use of mice models in oncology has gained momentum for drug discovery and therapeutics development, with several advancements expected to drive market growth. Notably, in February 2021, ExpreS2ion Biotech Holding and the University of Bologna collaborated on a research agreement to test the novel HER2-cVLP breast cancer vaccine program, including the lead candidate ES2B-C001, using proprietary state-of-the-art breast cancer mice models. Consequently, the application of mice models is poised to revolutionize drug discovery research, particularly in developing and validating various cancer therapies, including cancer immunotherapy, thereby fueling segment growth during the forecast period.

 

Based on region, North America segment is expected to grow during the forecast period. North America is expected to experience growth throughout the forecast period and maintain its dominance in the market. Among the countries in the region, the United States is leading the market due to factors such as increased healthcare expenditure, rising research and development activities, and a growing prevalence of communicable and non-communicable diseases. The primary driver for the mice model market in the United States is the increasing geriatric population. Market players in the country are engaged in various activities, including collaborations and agreements, which are expected to drive market growth during the forecast period.

 

Major companies operating in Global Humanized Mice Model Market are:

  • Allentown LLC
  • Charles River Laboratories International, Inc.
  • HBM Holdings
  • Horizon Discovery Group plc
  • Ingenious Targeting Laboratory
  • Janvier Labs
  • Trans Genic Inc.
  • PolyGene AG
  • Aragen Life Sciences Ltd.
  • The Andersons, Inc.

 

Download Free Sample Report

Customers can also request for 10% free customization on this report

 

“The humanized mice model market is expected to experience significant growth in the coming years. This growth can be attributed to the rising demand for personalized medicines that are developed using animal models, particularly mouse models. In this approach, human tissues are transplanted into immunodeficiency models, allowing researchers to observe disease manifestations. These models are then treated with different drugs or gene therapies to identify the most suitable treatment options. The ultimate goal is to provide patients with tailored and customized drugs, thereby enhancing their overall healthcare outcomes. As a result, these advancements are anticipated to have a considerable impact on the global market, influencing various factors such as research and development, pharmaceutical manufacturing, and patient care.,” said Mr. Karan Chechi, Research Director, TechSci Research, a research-based management consulting firm.

Humanized Mice Model Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Humanized Mice Models, Humanized Rat Models), By Application (Oncology, Immunology & Infectious Diseases, Toxicology, Others), By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutions), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global Humanized Mice Model Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Humanized Mice Model Market.

 

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com

Relevant News